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ABSTRACT
Adiponectin is an adipocyte-secreted adipokine with pleiotropic actions. Clinical 
evidence has shown that serum adiponectin levels are increased and that adiponectin 
can protect pancreatic beta cells against apoptosis, which suggests that adiponectin 
may play an anti-apoptotic role in pancreatic cancer (PC). Here, we investigated the 
effects of adiponectin on PC development and elucidated the underlying molecular 
mechanisms. Adiponectin deficiency markedly attenuated pancreatic tumorigenesis 
in vivo. We found that adiponectin significantly inhibited the apoptosis of both 
human and mouse pancreatic cancer cells via adipoR1, but not adipoR2. Furthermore, 
adiponectin can increase AMP-activated protein kinase (AMPK) phosphorylation and 
NAD-dependent deacetylase sirtuin-1 (Sirt1) of PC cells. Knockdown of AMPK or 
Sirt1 can increase the apoptosis in PC cells. AMPK up-regulated Sirt1, and Sirt1 can 
inversely phosphorylate AMPK. Further studies have shown that Sirt1 can deacetylate 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α), 
which can increase the expression levels of mitochondrial genes. Thus, adiponectin 
exerts potent anti-apoptotic effects on PC cells via the activation of AMPK/Sirt1/
PGC1α signaling. Finally, adiponectin can elevate β-catenin levels. Taken together, 
these novel findings reveal an unconventional role of adiponectin in promoting 
pancreatic cancers, and suggest that the effects of adiponectin on tumorigenesis are 
highly tissue-dependent.
INTRODUCTION
Pancreatic cancer, which is a gastrointestinal 
malignancy  with increasing incidence and mortality rates, 
exhibits dismal prognosis and no effective treatment, with 
a 5-year survival rate of less than 5%. Approximately 90% 
of pancreatic cancers originate in the duct of the glandular 
epithelium, which indicate that pancreatic cancer has a 
strong ability to metastasize [1, 2]. Many studies have 
shown that there is a correlation between obesity and 
cancer, although the precise mechanisms underlying this 
relationship remain obscure [3-5]. Adiponectin, which is 
encoded by the Adipoq gene, is an anti-diabetic and anti-
inflammatory adipokine, and its plasma concentration is 
decreased in obesity [3]. Adiponectin has two receptors, 
AdipoR1 and AdipoR2, both of which are highly 
expressed in tumor tissues of pancreatic cancer [2].
Many case-control and prospective studies have 
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shown that the serum concentration of adiponectin is 
decreased in breast cancer, hepatocellular carcinoma 
(HCC) and colorectal cancer [6-8]. In breast cancer, 
adiponectin can inhibit cell proliferation and invasion by 
decreasing phospho-AKT/GSK3β and β-catenin levels 
or activating the AMPK–S6K axis. Adiponectin inhibits 
hepatocellular carcinoma by increasing phosphorylation of 
c-Jun-N-terminal kinase (JNK) and inhibiting mammalian 
target of rapamycin (mTOR) phosphorylation [9]. 
Adiponectin also induces anti-angiogenesis and antitumor 
activity in sarcoma [10]. However, the association 
of serum adiponectin and pancreatic cancer remains 
controversial. One prospective study reported that the 
median plasma adiponectin concentration is lower in case 
subjects compared with control subjects [11]. In contrast, 
many other studies found higher serum adiponectin levels 
or a higher adiponectin/leptin ratio in pancreatic cancer 
patients who exhibited a positive or strong positive 
expression of AdipoR1 and AdipoR2 and that this higher 
level correlated strongly with the proinflammatory 
cytokine IL-6 [2, 12-14]. Importantly, adiponectin can 
protect against pancreatic beta cell apoptosis by the 
induction of Erk and Akt phosphorylation [15]. Taken 
together, these foundings suggested that adiponectin may 
play an anti-apoptotic role in pancreatic cancer, and thus 
requires further exploration.
In mechanistic studies, there is some indirect 
evidence that also shows that adiponectin may 
unconventionally regulate several proliferative signaling 
pathways under specific conditions [16, 17]. Barb et al. 
found that adiponectin can activate the mTOR pathway in 
PTEN-deficient cells and that this adiponectin stimulation 
of mTOR is mediated via AKT activation [16]. Habeeb 
et al. found that adiponectin inhibits colon cancer cell 
growth in glucose-containing medium, but can support cell 
survival in glucose-deprived medium via the induction of 
autophagy [17]. These findings suggested that adiponectin 
plays distinct roles in different environments and cancers. 
It has been reported that adiponectin can increase 
mitochondrial biogenesis and attenuate mitochondrial 
disorders via the activation of AMPK/PGC1α in the 
diabetic heart [18]. In melanoma cells, activation of 
PGC1α can increase mitochondrial energy metabolism and 
reactive oxygen species (ROS) detoxification capacities 
and reprogram cell metabolism to maintain cell growth 
and survival [19]. The metabolism and secretory activities 
of the pancreas are highly exuberant. Compared with other 
cancers, pancreatic cancer utilizes a noncanonical pathway 
of glutamine to increase the NADPH/NADP+ ratio, which 
can potentially maintain the cellular redox state [20]. 
Given the anti-apoptotic effect of adiponectin on the 
pancreas and heart [21], we hypothesized that adiponectin 
may increase mitochondrial biogenesis and inhibit 
apoptosis of pancreatic cancer cells via AMPK/Sirt1/
PGC1α. Consistent with our expectations, our in vitro 
and in vivo studies revealed that adiponectin can strongly 
promote pancreatic cancer cell growth via the inhibition 
of apoptosis, and we simultaneously investigated the 
underlying molecular mechanisms.
RESULTS
Adiponectin deficiency inhibits pancreatic cancer 
cell growth and metastasis in C57BL/6 mice
H7 and Panc02 mouse pancreatic cancer cell lines 
were derived from a C57BL/6 background [22, 23]. 
To examine the role of adiponectin in the regulation of 
pancreatic cancer growth, orthotopic inoculation of H7 
cells was performed in adiponectin (APN) -KO and WT 
mice. The size and weight of the resulting tumor were 
measured. Tumors from WT mice were notably larger 
and heavier compared to the tumors from APN KO mice 
(Figure 1A, B). Unexpectedly, adiponectin deficiency 
significantly reduced the metastasis of H7 cells in the 
intestine, lung, and kidney (Supplementary Figure S1A, 
B, and C). H&E staining of tissue sections more clearly 
confirmed these results (Supplementary Figure S1D). On 
the basis of these results, we concluded that adiponectin 
plays an unorthodox role in the regulation of pancreatic 
cancer growth and metastasis. 
To further confirm the relationship between 
adiponectin and pancreatic cancer, we subcutaneously 
injected H7 and Panc02 cells into APN KO and WT mice. 
H7 and Panc02 cells were able to grow in both APN KO 
and WT mice, and there was a significant reduction in 
tumor size and tumor weight in APN KO mice, which 
suggested that adiponectin could promote pancreatic 
cancer growth in vivo (Figure 1C, D, Supplementary 
Figure S2A, B). We used quantitative PCR and ELISA to 
further determine the authenticity of the APN knockout 
mice. There is nearly no expression of adiponectin in 
APN KO mice compared with WT mice (Supplementary 
Figure S2C, D). Taken together, these results suggested 
that adiponectin promoted pancreatic cancer cell growth.
Adiponectin exhibits an anti-apoptotic role in 
pancreatic cancer
It has been proposed that adiponectin can reduce 
apoptosis in the heart and pancreas via noncanonical 
pathways [15, 21, 24]. Given the role of adiponectin 
in the promotion of pancreatic cancer cell growth, we 
investigated whether adiponectin promoted pancreatic 
cancer growth by inhibiting apoptosis of pancreatic cancer 
cells. Adiponectin can significantly inhibit the apoptosis 
of pancreatic cancer in vivo by decreasing the levels of 
the apoptotic marker cleaved-caspase 3 (Figure 1E). 
TUNEL-stained H7 tumor sections were consistent with 
Western blotting results (Figure 1F). To determine whether 
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Figure 1: Adiponectin deficiency inhibits pancreatic cancer cell growth in vivo. (A, B) 5×105 H7 cells were injected into the 
orthotopic pancreas per mouse (WT: n=8, KO: n=6). The mice were sacrificed two weeks after inoculation and the tumors were collected, 
measured, weighed and imaged. (C, D) WT and APN KO mice were subcutaneously challenged with H7 cells (1×106 cells per mice, n=16 
per group) in the flank. The tumor size of H7 cells was monitored every three days for 30 days. Twenty and 30 days after the inoculation of 
H7 cells, the mice were sacrificed, and the tumors were collected, weighed and imaged. (E) H7 tumor lysates from APN KO and WT mice 
were analyzed using immunoblotting with the indicated antibodies. (F) Representative TUNEL stained H7 tumor section from APN KO and 
WT mice. The values represent the mean ± SEM of three independent experiments performed in triplicate. **: 0.001<p<0.01; ***: p<0.001.
Figure 2: Adiponectin exerts anti-apoptotic effects in mouse and human pancreatic cancer cells. (A) H7 cells were treated 
with adiponectin (0 or 10 μg/ml) and doxorubicin (2 μM) in 2% FBS medium for 24 hours, and apoptosis was then detected using Annexin 
V. (B) Apoptosis of Panc-1 cells after treatment with adiponectin (0 or 10 μg/ml) and doxorubicin (6 μM) in 2% FBS medium for 24 hours. 
(C, D) The cells were treated as described in A and B, and the levels of cleaved- caspase 3 in H7 and Panc-1 cells were analyzed using 
immunoblotting. (E) Cell death assay results. Twenty-four hours after APN and doxorubicin treatment, the number of dead cells of H7 
was quantified and expressed as the percentage of total cells. (F) Cell proliferation assay results. Twenty thousand H7 cells were plated in 
12-well plates and treated with adiponectin (1-10 μg/ml) and doxorubicin (2 μM) in 2% FBS medium for 48 hours, and then quantification. 
The cell number from three independent experimental wells was plotted. The values represent the mean ± SEM of three independent 
experiments performed in triplicate. *: 0.01<p<0.05; **: 0.001<p<0.01.
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adiponectin can protect pancreatic cancer cells against 
apoptosis in vitro, mouse H7 and human Panc-1 pancreatic 
cancer cell lines were directly treated with adiponectin 
and doxorubicin. We found that adiponectin inhibited the 
apoptosis induced by doxorubicin in both H7 and Panc-
1 cells (Figure 2A, B). This decreased apoptosis was 
mediated via inhibition of cleaved-caspase 3 expression 
(Figure 2C, D). To further confirm the biological activity 
of adiponectin, we treated HepG2 (human HCC cell 
lines) cells with adiponectin and found that adiponectin 
increased apoptosis induction in HepG2 cells by more than 
one-fold (Supplementary Figure S3A, B). Western blotting 
analyses showed that adiponectin could increase the levels 
of cleaved-caspase 3 in HepG2 cells (Supplementary 
Figure S3C, D) [9]. Moreover, adiponectin can decrease 
pancreatic cancer cell death and increase proliferation 
(Figure 2E, F). Taken together, these results suggested 
that adiponectin could decrease the apoptosis and death 
of pancreatic cancer cells via the suppression of caspase 
3 activation.
Adiponectin-induced anti-apoptosis effects are 
mediated by AdipoR1 and not AdipoR2
To determine the role of AdipoR in pancreatic 
cancer growth, we first tested the expression of AdipoRs 
using RT-PCR in H7 and Panc02 cell lines and found that 
both cell lines expressed AdipoR1 and AdipoR2. AdipoR1 
expression levels were relatively higher compared to 
AdipoR2 in both cell lines (Supplementary Figure S4A, 
B). Next, we suppressed AdipoR1 or AdipoR2 expression 
(Supplementary Figure S4C-F) and found that knockdown 
of AdipoR1, but not that of AdipoR2, resulted in a 2.5-fold 
increase in the percentage of apoptotic H7 cells (Figure 
3A).
Figure 3: Suppression of AdipoR1 promotes apoptosis and inhibits proliferation. (A) Annexin V analysis of apoptosis after 
AdiopR1/2 knockdown in H7 cells treated with adiponectin (10 μg/ml) or doxorubicin (2 μM) in 2% FBS medium for 24 hours. (B, C) 
Tumor formation assay results after knockdown of AdipoRs. 1×106 H7 cells with the indicated expression conditions of AdipoRs were 
injected subcutaneously into 6- to 8- week-old C57BL/6 mice. The tumor size was monitored once a week for three weeks. Next, the 
mice were sacrificed, and the tumors were resected, measured and weighed (n=8 mice per group, ***: shAdipoR1 and Scramble; ##: 
shAdipoR1 and shAdipoR2). (D) Immunofluorescence of Ki-67 in H7 tumor sections after AdipoR knockdown. Scale bars, 100 μm. The 
values represent the mean ± SEM of three independent experiments performed in triplicate. *: 0.01<p<0.05; ** or ##: 0.001<p<0.01; ***: 
p<0.001.
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To further investigate the role of AdipoRs, 
AdipoR1 or AdipoR2 knockdown H7 or Panc02 cells 
and scramble cells were subcutaneously injected into 
C57BL/6 mice. Knockdown of AdipoR1 in H7 and 
Panc02 cells significantly reduced tumor size and tumor 
weight, suggesting that AdipoR1 was more important for 
adiponectin promotion of pancreatic cancer growth (Figure 
3B, C, Supplementary Figure S4G, H). We also detected 
the effect of shRNA on the targeting AdipoRs following 
in vivo studies, and found that the expression levels of 
both AdipoRs were effectively inhibited (Supplementary 
Figure S5A-D). In addition, AdipoR1 knockdown 
markedly decreased the expression of Ki-67, which 
indicated that AdipoR1 was indispensable for adiponectin-
induced proliferation of pancreatic cancer cells (Figure 
3D, Supplementary Figure S4I). Taken together, these 
results demonstrated that suppression of AdipoR1, but not 
AdipoR2, activates the intrinsic apoptotic pathway.
AMPK is a pivotal mediator of adiponectin-
suppression of caspase 3 activity
To further investigate the anti-apoptotic effect of 
adiponectin on pancreatic cancer cells, we next evaluated 
the activity of caspase 3 of pancreatic cancer cells after 
treatment with adiponectin using a new experimental 
technology [25]. Adiponectin significantly suppressed 
caspase 3 activity induced by doxorubicin in pancreatic 
cancer cells (Figure 4A). AMPK has been hypothesized 
to be a crucial sensor of energy status and plays important 
pleiotropic roles in cellular responses to metabolic stress 
[26-28]. To investigate the role of AMPK in pancreatic 
cancer growth regulated by adiponectin, H7 tumor lysates 
obtained from APN KO and WT mice were detected 
using Western blotting analyses with anti-phospho-
AMPK antibody. Adiponectin significantly increased 
AMPK phosphorylation, and this effect was accompanied 
with decreased levels of cleaved-caspase 3, suggesting 
that adiponectin inhibited the apoptosis of pancreatic 
cancer cells most likely via AMPK (Figure 4B). These 
results were consistently found in our in vitro studies. 
Furthermore, AdipoR1 knockdown resulted in a more 
than a 2-fold inhibition of AMPK phosphorylation, 
significant activation of caspase 3, and down-regulation 
of cyclinD1 (Figure 4C). To investigate the role of AMPK 
in pancreatic cancer regulated by adiponectin, H7 and 
Panc-1 cells lysates treated with adiponectin were detected 
using immunoblotting analyses and showed higher levels 
of phospho-AMPK and lower levels of cleaved-caspase 3 
(Figure 4D). AMPK knockdown resulted in a more than 
3-fold induction in the percentage of apoptotic cells in 
H7 cells (Figure 4E), and this result was consistent with 
western blotting results (Figure 4F). Taken together, these 
results suggested that AMPK plays an important role in 
regulating pancreatic cancer cell apoptosis via adiponectin.
Figure 4: Adiponectin-induced AMPK phosphorylation is essential for the anti-apoptotic effect. (A) Fluorescence 
demonstrating the caspase 3 activity of mouse H7 or human Panc-1 cells treated with full-length mouse or human adiponectin (0 or 10 μg/
ml) combined with doxorubicin (2 μM or 6 μM) for 24 hours. Scale bars, 50 μm. (B) H7 tumor lysates from APN KO and WT mice were 
analyzed using immunoblotting with the indicated antibodies. (C) Western blotting analysis of pAMPK, cleaved-caspase 3, cyclinD1 in 
H7 cells stably expressing control or AdipoR1/2 shRNA. (D) Mouse H7 or human Panc-1 cells were treated with full-length mouse or 
human adiponectin (0 or 10 μg/ml) combined with doxorubicin (2 μM or 6 μM) for 24 hours. Total protein lysates were analyzed using 
immunoblotting with the indicated antibodies. (E) Annexin V analysis of apoptosis after AMPK knockdown in H7 cells treated with 
doxorubicin (0 or 2 μM). (F) Western blotting analysis of Sirt1 and Caspase 3 in H7 cells stably expressing control or AMPK shRNA. The 
values represent the mean ± SEM of three independent experiments performed in triplicate. *: 0.01<p<0.05; **: 0.001<p<0.01.
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Adiponectin inhibits apoptosis of pancreatic 
cancer cell via activation of AMPK-Sirt1-PGC1α 
signaling
Consistent with previous studies [26, 29, 30], we 
found that AMPK knockdown down-regulated Sirt1 
(Figure 4F). Sirt1, which belongs to the family of sirtuins, 
is a protein deacetylase that is dependent on nicotine 
adenine dinucleotide (NAD) [31, 32]. Several studies 
have shown that inhibition of Sirt1 and Sirt2 in human 
pancreatic cancer cell lines can significantly inhibit cell 
proliferation and induce apoptosis [33-35]. Clinical 
epidemiological studies have also found that Sirt1 is 
overexpressed in pancreatic cancer tissues at both the 
mRNA and protein levels compared with adjacent normal 
pancreatic tissues [34, 36]. Adiponectin deficiency can 
significantly decrease the level of Sirt1 but has no effect 
on Sirt2, which suggests that inhibition of apoptosis by 
adiponectin is dependent on Sirt1 and not on Sirt2 (Figure 
5A). The in vitro results further showed that adiponectin 
can up-regulate Sirt1 levels in both H7 and Panc-1 
cells (Figure 5B). Sirt1 knockdown resulted in higher 
apoptosis in H7 and Panc-1 cells (Figure 5C, D) and Sirt1 
Figure 5: Adiponectin modulates the AMPK-Sirt1-PGC1α axis. (A) H7 tumor lysates from APN KO and WT mice were 
analyzed using immunoblotting with the indicated antibodies. (B) Mouse H7 or human Panc-1 cells were treated with full-length mouse 
or human adiponectin (0 or 10 μg/ml) combined with doxorubicin (2 μM or 6 μM) for 24 hours. Total protein lysates were analyzed using 
immunoblotting with the indicated antibodies. (C) Western blotting analysis of pAMPK, AMPK, cleaved-caspase 3 in H7 cells stably 
expressing control or Sirt1 shRNA. (D) Annexin V analysis of apoptosis after Sirt1 knockdown in H7 cells treated with doxorubicin (2 
μM) or Panc-1 cells treated with doxorubicin (6 μM) for 12 hours. (a, c) Annexin V diagram. (c, d) quantification of the percentage of 
apoptotic cells using the Annexin V assay. (e) Western blotting analysis of Sirt1 levels in Panc-1 cells. (E) Fluorescence demonstrated the 
caspase 3 activity of mouse H7 cells treated with doxorubicin (2 μM) or human Panc-1 cells treated with doxorubicin (6 μM) for 12 hours 
after Sirt1 knockdown. Scale bars, 50 μm. (F) Sirt1 knockdown H7 cells were harvested and subjected to immunoprecipitation using anti-
PGC1α antibody, and western blots were performed for the indicated proteins. The values represent the mean ± SEM of three independent 
experiments performed in triplicate. *: 0.01<p<0.05; **: 0.001<p<0.01.
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knockdown also activated the caspase 3 activity (Figure 
5E). We found that AMPK can modulate Sirt1 levels 
(Figure 4F). Expectedly, Sirt1 knockdown also decreased 
AMPK phosphorylation (Figure 5C).
Peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (PGC1α) is a regulator of 
mitochondrial biogenesis and function [19, 37]. It has been 
reported that AMPK-Sirt1-PGC1α is an important energy-
sensing metabolic pathway [38]. We found that tumor cells 
from APN KO mice exhibited increased acetylation levels 
of PGC1α, which suggested that adiponectin deficiency 
can inhibit the activity of PGC1α (Figure 5A, B). To test 
if Sirt1 can deacetylate PGC1α, immunoprecipitation was 
performed using anti-PGC1α antibody. Consistent with 
expectations, Sirt1 knockdown increased the acetylation 
levels of PGC1α (Figure 5F). Taken together, these results 
suggested that adiponectin could activate AMPK-Sirt1-
PGC1α signaling.
Adiponectin enhances mitochondrial gene 
expression via PGC1α
Consistent with its anti-apoptosis effect, 
adiponectin-treated H7 cells showed a lower decrease in 
mitochondrial membrane potential, as determined using 
the J-aggregation fluorescence assay (Figure 6A, B). We 
further investigated the anti-apoptotic role of PGC1α 
activated by adiponectin in pancreatic cancer cells and 
found that PGC1α knockdown resulted in a 2.5-fold 
increase in the percentage of apoptotic H7 cells, which 
was consistent with Western blotting results (Figure 
6C, D). Expectedly, adiponectin deficiency resulted in a 
decrease in the levels of mitochondrial genes (Figure 6E). 
Sirt1 or PGC1α knockdown also resulted in a decrease 
in the levels of mitochondrial genes (Figure 6F). Taken 
together, these results suggested that adiponectin can 
protect the mitochondrial membrane potential and increase 
Figure 6: Adiponectin protects the functional integrity of the mitochondrial membrane, and exerts potent anti-
apoptotic effects. (A) Mitochondrial membrane potential detection. H7 cells were treated with full-length mouse adiponectin (0 or 
10 μg/ml) combined with doxorubicin (2 μM) for 24 hours and measured using the JC-1 dye. Healthy mitochondria were polarized, and 
JC-1 was rapidly taken up by these mitochondria to form JC-1 aggregates. When the mitochondrial membrane was damaged, JC-1 does 
not accumulate in the mitochondria and flows into the cytoplasm as monomers. (B) Quantification of the percentage of J-monomer. (C) 
Annexin V analysis of apoptosis after PGC1α knockdown in H7 cells. (D) Western blotting analysis of cleaved-caspase 3 in PGC1α 
knock-down and control H7 cells. (E) mRNA expression levels of mitochondrial genes in H7 tumor cells from APN KO and WT mice. (F) 
mRNA expression levels of mitochondrial genes in Sirt1 or PGC1α knockdown H7 cells. The values represent the mean ± SEM of three 
independent experiments performed in triplicate. *: 0.01<p<0.05; **: 0.001<p<0.01.
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the expression of mitochondrial genes via the activation 
of PGC1α.
Inhibition of caspase 3 modulates the degradation 
of β-catenin and increases the expression of 
cyclinD1
We found that adiponectin can promote H7 cell 
proliferation in a dose-dependent manner (Figure 2F). 
Next, we investigated the mechanism responsible for this 
increase in cell number after treatment with adiponectin 
and found that tumor cells from APN KO mice expressed 
less cyclinD1 compared to WT mice (Figure 7A). 
CyclinD1 is responsible for the cell cycle progression 
from the G1 to S phase, where the cell cycle transition 
from the G2 to the M phase is controlled by cyclinB 
[39, 40]. Cdc-2 and its phosphorylation status, which are 
coordinated with cyclinB, exhibited no change between 
APN KO and WT mice (Figure 7A), which indicated 
that adiponectin promoted pancreatic cancer growth via 
the induction of cell cycle transition from the G1 to S 
phase. It is known that β-catenin can bind to the cyclinD 
promoter and activate its expression [41]. The total level 
of β-catenin and c-myc in H7 tumors from APN KO mice 
is lower compared to that obtained from WT mice, which 
was consistent with the results of the in vitro study (Figure 
7B, C).
β-catenin is a central effector in Wnt signaling. [42]. 
However, we found that adiponectin has not effect on the 
phosphorylation of GSK3β, Wnt3a and Wnt5a (Figure 7B, 
Supplementary Figure S6A, B). Adiponectin also has no 
Figure 7: Adiponectin can elevate β-catenin and cyclinD1 levels. (A, B) H7 tumor lysates from APN KO and WT mice were 
analyzed using immunoblotting with the indicated antibodies. (C) Western blotting analysis of H7 cells treated as shown in Figure 2A using 
the indicated antibodies. (D) Western blotting analysis of β-catenin, caspase 3 in H7 cells stably expressing control or caspase 3 shRNA 
after treatment with glucose (0 or 25 mΜ) for 24 hours. The values represent the mean ± SEM of three independent experiments performed 
in triplicate. *: 0.01<p<0.05; **: 0.001<p<0.01. (E) A model based on our studies. In pancreatic cancer, adiponectin protects the functional 
integrity of the mitochondrial membrane via the activation of AMPK-Sirt1-PGC1α signaling and exerts potent anti-apoptotic effects. 
Decreased apoptosis inhibits the degradation of β-catenin, and promotes the cyclinD1 expression.
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effect on the activity of Erk (Figure 7B, Supplementary 
Figure S6B), which suggests that there is a noncanonical 
regulatory pathway for β-catenin in pancreatic cancer 
cells. Numerous studies have shown that caspase 3 can 
induce the degradation of β-catenin independent of 
GSK3β and Erk activity [43, 44]. We found that a reverse 
regulatory relationship exists between caspase 3 and 
β-catenin in H7 cells (Figure 7D). In addition, glucose 
starvation-induced caspase 3 activation could decrease the 
level of β-catenin, and deletion of caspase 3 can decrease 
the degradation of β-catenin (Figure 7D). Taken together, 
these results suggested that upregulation of β-catenin and 
cyclinD1 by adiponectin is mediated via a decrease in the 
apoptosis of pancreatic cancer cells.
DISCUSSION
Although it has been reported that adiponectin 
plays a positive role in many cancers, the relationship 
between adiponectin and pancreatic cancer remains 
unclear [9, 10, 42, 45]. Here we provide the first evidence 
that adiponectin KO mice exhibit growth inhibition of 
pancreatic cancer cells.
Unlike most other cancers, our in vivo studies 
showed that adiponectin deficiency could significantly 
alleviate pancreatic cancer growth and metastasis, 
suggesting that there is an unconventional role of 
adiponectin in the promotion of pancreatic cancer 
progression. Further experiments showed that adiponectin 
inhibited the apoptosis of pancreatic cancer cells via 
AdipoR1, which was consistent with the effect on 
myocytes. In hepatocellular carcinoma, adiponectin 
induced apoptosis via activation of the AMPK-JNK-
caspase3 pathway [9]. Adiponectin stimulated AMPK 
and extracellular Ca2+ influx, which were involved in 
glucose and lipid metabolism partially via mitochondrial 
biogenesis in cardiac myocytes, pancreatic beta cells, 
and the liver [24]. To investigate whether the anti-
apoptotic effect of adiponectin in pancreatic cancer cells 
is mediated by AMPK, we detected the phosphorylation 
level of AMPK in AdipoR-knockdown H7 cells treated 
with adiponectin and found that AdipoR1 knockdown 
resulted in a decreased level of AMPK phosphorylation 
accompanied with an increase in caspase 3 activation. 
AMPK plays a distinct role in pancreatic cancer cells, 
which is consistent with our expectations. We suspected 
that pancreatic cancer cells might reprogram their 
metabolism via AMPK signaling to meet the anabolic and 
energetic demands necessary for growth and survival.
AMPK can upregulate Sirt1 and induce 
deacetylation of PGC1α [18, 38]. It has been reported 
that PGC1α can reprogram cancer cell metabolism and 
enhance mitochondrial biogenesis via the activation of a 
series of mitochondrial genes [19]. Our studies showed 
that adiponectin can upregulate Sirt1 levels, and Sirt1 
can conversely phosphorylate AMPK. The levels of 
mitochondrial genes were increased to different levels in 
H7 tumors cells from WT mice compared with KO mice, 
which was comfirmed by Sirt1 or PGC1α knockdown. 
Moreover, PGC1α knockdown in H7 cells induced higher 
levels of apoptosis compared with control cells and 
resulted in a significant activation of caspase 3. These 
results revealed that adiponectin protected pancreatic 
cancer cells against apoptosis via the activation of PGC1α 
and mitochondrial genes. Holland et al. reported that 
adiponectin can significantly reduce hepatic ceramide 
levels and blood glucose levels via the activation of 
ceramidase activity, which can phosphorylate AMPK 
through the activation of calcium influx and protect 
pancreatic beta cells against apoptosis [46]. However, 
it is still unclear whether adiponectin can activate the 
AMPK-Sirt1-PGC1α signaling axis via the activation of 
ceramidase activity in pancreatic cancer.
Our results have also shown that adiponectin was 
able to induce the cell cycle transition from the G1 to 
S phase via the upregulation of cyclinD1 expression, 
which was transcriptionally activated by β-catenin, but 
did not affect the transition from the G2 to M phase in 
H7 cells. Several studies have reported that adiponectin 
can decrease the phosphorylation of GSK3β and increase 
the phosphorylation of β-catenin, which resulted in its 
degradation [42, 47, 48]. Other research studies have found 
that adiponectin-induced Erk and AKT phosphorylation 
protected against pancreatic beta cell apoptosis and 
ameliorated doxorubicin-induced cardiotoxicity [15, 
49]. Erk has been shown to increase the transcriptional 
activity of β-catenin via a Wnt-dependent or -independent 
pathway [50, 51]. Unexpectedly, the phosphorylation 
levels of AKT, Erk1/2 and GSK-3β were not all affected 
by adiponectin in pancreatic cancer cells, which suggested 
that an unconventional pathway regulates β-catenin. We 
found that decreased apoptosis can upregulate β-catenin, 
which can be blocked by the deletion of caspase 3 in H7 
cells [43, 44]. We proposed that these apoptotic cells might 
activate the ubiquitin-conjugating enzyme and target 
β-catenin for degradation via the proteasome. In addition, 
we found that adiponectin deficiency significantly 
inhibited the metastasis of H7 cells, which is a highly 
metastatic cell line derived from the Panc02 cell line. The 
mechanism underlying this inhibition of metastasis by 
adiponectin remains to be explored.
In summary, this study revealed that adiponectin 
plays a role in inhibition of an intrinsic apoptotic pathway 
and promotion of cell survival in pancreatic cancer. 
Adiponectin exerted potent anti-apoptotic effects via 
the activation of AMPK/Sirt1/PGC1α signaling. Taken 
together, these findings suggested that the effects of 
adiponectin on tumorigenesis are highly tissue-dependent 
and different cancers should use different treatment 
strategies to target adiponectin.
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MATERIALS AND METHODS
Mice and animal studies
Female 6- to 8-week-old C57BL/6 mice were 
purchased from the Academy of Military Medical Science 
(Beijing, China). Adiponectin knock-out mice (Adipoq-/-) 
in a C57BL/6 background were generated at the laboratory 
of Lawrence Chan (Baylor College, University of Texas, 
Houston) [52]. All animals were raised under 12 hr light-
dark cycles at 22-24oC with free access to food and water. 
All of the animal studies were approved by the Animal 
Ethics Committee of Tianjin Medical University. For the 
ectopic tumor model, adiponectin KO and WT mice were 
challenged with H7 (1×106 cells per mouse) or Panc02 
cells (2×106 cells per mouse) in the flank. All of the tumor 
cell lines formed solid tumors in mice. Tumors were 
measured using digital vernier calipers, and their sizes 
were calculated as: TV= (Length) × (Width)2 /2 every 
three days. All of the mice were sacrificed four weeks 
after the initial implantation. Tumors, spleen, lymph 
gland, lung and liver tissues were collected and subjected 
to further analysis. For the orthotopic tumor model, an 
approximately 1-cm-long slit was cut into the side of 
the mice abdomen next to the pancreas, 5×105 H7 cells 
were then injected into the pancreas, and then the slit was 
sutured. The mice were sacrificed two weeks after surgery, 
and the ascitic fluid and tumor metastasis was recorded. 
Tumors were collected, measured, weighed and imaged.
Cell culture and reagents
Mouse ductal pancreatic adenocarcinoma cell line 
Panc02 was originally established by Corbett et al [22]. 
The highly metastatic Panc02-H7 cell line established 
using an in vivo selection method by Wang et al [23]. 
B16, Panc-1 and HepG2 cells were purchased from 
ATCC. Panc02, H7 and Panc-1 were cultured in DMEM 
(Gibic) supplemented with 10% fetal bovine serum (FBS) 
(Hyclone). HepG2 and B16 cells were cultured in 1640 
(Gibic) supplemented with 10% fetal bovine serum 
(FBS) (Hyclone). All cells were cultured at 37oC in an 
atmosphere of 5% CO2 in air. The mouse and human 
full-length adiponectin produced from HEK293 cells 
were purchased from Bio-Way Biotechnology (Guang 
Zhou, China). Mouse adiponectin (ADP) ELISA Kit was 
purchased from Bio-Way Biotechnology (Guang Zhou, 
China), and performed following the manufacture’s 
instructions.
Apoptosis and TUNEL assay
The Apoptosis Kit-Annexin V Alexa Fluor® 488 
& Propidium Iodide (Life Technologies) and TUNEL 
assay (TREVIGEN®) was performed following the 
manufacture’s instructions.
Antibodies, western blotting analyses and 
immunoprecipitation
Antibodies for cleaved-caspase 3 (Asp175), 
caspase 3, phospho-AMPK (Thr172), AMPK, cyclin 
D1, acetylated-lysine, phospho-Akt (Ser473), phospho-
GSK-3β (Ser9), phospho-cdc2 (Tyr15), cdc2, c-myc, 
phospho-Erk1/2 (Thr202/Tyr204) were purchased from 
Cell Signaling. β-catenin, Sirt-1, Sirt-2 were purchased 
from Abcam. PGC1α was purchased from Millipore. 
β-actin was purchased from Sungene. Whole cell lysate 
was prepared using RIPA lysis buffer in the presence 
of protease inhibitors. Protein concentrations were 
determined using the bicinchoninic acid (BCA) method 
(Biomed, Beijing, China). Total cell lysates were separated 
using 8%-12% SDS-PAGE, transferred onto PVDF 
membranes, and then detected using various primary 
antibodies. The antibody-antigen complexes were detected 
using the Chemiluminescent HRP Substrate (Millipore, 
MA, USA).
For immunoprecipitations, cells were lysed in lysis 
buffer (50 mM Tris-HCl at pH 7.4, 0.2 mM EDTA, 150 
mM NaCl, 3% NP-40, 1 mM phenyl methylsulfonyl 
fluoride (PMSF) and, Protease inhibitor cocktail). Equal 
amounts of cell extracts were incubated with anti-PGC1α 
antibodies. Subsequent immunoblots were performed as 
described above.
Cell death assay
H7 Cells were plated 1×105 per well of a 12-well 
plate in duplicate plates for 12 h. Next, the cells were 
treated with mouse full-length adiponectin (0 or 10 μg/
ml) along with doxorubicin (3 or 4 μM). After 24 h, all 
cells in the supernatant as well as adherent cells were 
collected from each well and resuspended in an equal 
volume of 1× PBS. The cells were diluted 1:10 in PBS 
and an equal volume of trypan blue dye was added to 
each sample. Next, the total number of cells and the total 
number of blue cells (dead cells that did not exclude the 
dye) were quantified using a hemocytometer. Cell death 
was presented as the percentage of dead cells compared 
with the total number of cells for each well.
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Cell proliferation
In this study, 20,000 H7 cells were plated in 
12-well plates and treated with adiponectin (1-10 μg/
ml) accompanied with doxorubicin (2 μM) in 2% FBS 
medium for 48 hours, Next, the cells were quantified 
and the numbers were plotted from three independent 
experimental wells.
RNA isolation and RT-PCR
Total RNA was isolated using Trizol reagent 
(Invitrogen, Carlsbad, USA). Total RNA (2 μg) was used 
for synthesis of first-strand cDNA using M-MLV reverse 
transcriptase (Invitrogen, Beijing, China). Quantitative 
real-time PCR was performed using the SYBR green 
mix (Newbio industry, Beijing, China). The reactions 
were performed with a 7500 fast. Data were displayed 
as 2-△△Ct values and were representative of at least 
three independent experiments. Sequences of the RT-PCR 
primers were as follows (5′ - 3′):
GAPDH(CCATGTTCGTCATGGGTGTGAACCA 
and GCCAGTAGAGGCAGGGATGATGTTC);
AdipoR1(AATGGGGCTCCTTCTGGTAAC and 
GGATGACTCTCCAACGTCCCT); 
AdipoR2(GCCAAACACCGATTGGGGT and 
GGCTCCAAATCTCCTTGGTAGTT); 
IDH3A(ACAGGTGACAAGAGGTTTTGC and 
CTCCCACTGAATAGGTGCTTTG); 
Ndufs3(TGGCAGCACGTAAGAAGGG 
and CTTGGGTAAGATTTCAGCCACAT); 
Cytc(GGTAACTGCAACTACTACTGTGG and 
CTTGATCTCGATCTTCGACATGG);
Cox5A(GCCGCTGTCTGTTCCATTC and 
GCATCAATGTCTGGCTTGTTGAA); 
ATP5g1(TTCTCCAGCTCTGATTCGCTC and 
CCGGGAAATGACACTGGTCT); 
ERRα(AGGTGGACCCTTTGCCTTTC and 
GGCATGGCGTACAGCTTCT).
Constriction of recombinant lentivirus vectors 
and viral packaging
Replication-incompetent recombinant lentivirus 
expressing shRNAs were constructed using the 
PLKO.1 puro cloning vector (Addgene) according 
the Addgene’s instructions. PLKO.1 is a replication-
incompetent lentiviral vector selected by the puromycin 
for the expression of shRNAs. The expression of 
shRNA is controlled by the human U6 promoter. A 21-
mer oligonucleotide sequence was used against mouse 
AdipoR1, AdipoR2 and PGC1α. The oligonucleotides 
were annealed and ligated into the AgeI-EcoR1 sites of 
the shRNA vector PLKO.1-puro. To produce lentiviral 
particles, PLKO.1 shRNA plasmid or scramble shRNA 
plasmid (as control) with psPAX2 packing plasmid and 
pMD2.G envelope plasmid were transfected into 293T 
cells using X-tremeGENE HP DNA transfection Reagent 
(Roche). The biological titer of the purified virus was 
determined in 293T cells using serial dilution method. To 
select stable cell lines, viral supernatant was added to 10-
cm dish for 24 hr, and then replaced with fresh medium for 
an additional 24 hr. Next, puromycin (8 μg/ml) was used 
to select stable cell lines. Sequences of the shRNAs were 
available as follows:
M(mouse)-shAdipoR1:5′-CCGGGAGACTGGCA
ACATCTGGACACTCGAGTGTCCAGATGTTGCCAG
TCTCTTTTTG-3′;
M-shAdipoR2:5′-CCGGGCTTAGAGACACCTG
TTTGTTCTCGAGAACAAACAGGTGTCTCTAAGCT
TTTTG-3′;
M-shAMPK:5′-CCGGGAATCCTCATAGACCTT
ATTACTCGAGTAATAAGGTCTATGAGGATTCTTTT
TG-3’;
M-shSirt1#1:5’-CCGGCTAGACCAAAGAATGG
TATTTCTCGAGAAATACCATTCTTTGGTCTAGTTT
TTG-3’; 
M-shSirt1#2:5’-CCGGAGTGAGACCAGTAGCA
CTAATCTCGAGATTAGTGCTACTGGTCTCACTTTT
TG-3’;
H(human)-shRNA-Sirt1#1:5’-CCGGGCAAAGCC
TTTCTGAATCTATCTCGAGATAGATTCAGAAAGGC
TTTGCTTTTTG-3’;
H-shRNA-Sirt1#2:5’-CCGGGATGATCAAGAGG
CAATTAATCTCGAGATTAATTGCCTCTTGATCATC
TTTTTG-3’;
M-shPGC1α#1:5′-CCGGCCAGAACAAGAACA
ACGGTTTCTCGAGAAACCGTTGTTCTTGTTCTGG
TTTTTG-3′;
M-shPGC1α#2:5′-CCGGCGTGTGATTTACGTTG
GTAAACTCGAGTTTACCAACGTAAATCACACGTT
TTTG-3′.
Caspase 3 activity assay
Cells were transfected using lenti-virus stably 
expressing caspase-3-like protease activation indicators 
(virus was a kind gift from Binghui Li). The cells 
were then treated with adiponectin or shRNA, and the 
fluorescence was recorded after 24 hours or other time 
points.
Immunohistochemistry and Immunofluorescence
For immunohistochemical studies, 5μm paraffin-
embedded tissue sections were deparaffinized and 
hydrated, followed by several washes with distilled water. 
The slides were then treated with antigen thermal retrieval 
in 0.01M citric acid- sodium citrate buffer (pH 6.0). After 
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several washes with PBS, the slides were incubated with 
2% bovine serum albumin diluted in PBS for 30 min at 
room temperature. Primary antibodies were dropped 
onto slides incubated at 4°C overnight. After washing 
with PBS, secondary antibodies (goat anti-rabbit IgG, 
Invitrogen) labeled with biotin were added and incubated 
at room temperature for 30 min. The slides were mounted 
with DAB (Cell Signaling) after washed with PBS.
For immunohistochemical studies, briefly, cells were 
fixed with 4% formaldehyde for 5min, and then incubated 
with 2% bovine serum albumin diluted in PBS for 30 min 
at room temperature. Cells were incubated with primary 
antibodies at 4°C overnight. After washing with PBS, 
secondary antibodies (donkey anti-rabbit IgG, Invitrogen) 
labeled with Alexa Fluor 555 were added and incubated 
at room temperature for 30 min. The slides were mounted 
with Fluomount-G containing DAPI (eBioscience) after 
PBS washing.
Statistical analysis
All results were derived from at least three 
independent experiments. The data were expressed as 
the mean ± SEM and analyzed using a standard two-
tailed Student’s t-test using EXCEL (Microsoft 2007). 
Differences with p < 0.05 were statistically significant.
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